Navigation Links
Controversial drug shown to act on brain protein to cut alcohol use

Medication against nicotine addiction is nowadays readily available. However, a similar and equally dangerous addiction, alcoholism, can't yet be controlled by drugs. Or can it be? Researchers from the University of California in San Diego identified a natural compound able to block alcohol addiction in rodents. We can only hope that anti-alcoholism patchs or gum will be available in a close future; it would help fix a problem that we've been struggling with for ages. A naturally occurring hallucinogen advocated by some clinicians as a potent anti-addiction drug has been rigorously studied for the first time, confirming its ability to block alcohol craving in rodents, and clarifying how it works in the brain. The new research findings about the drug Ibogaine open the way for development of other drugs to reverse addiction without Ibogaine's side effects, potentially adding to the small arsenal of drugs that effectively combat addiction.

Derived from a West African shrub, Ibogaine has been championed for years by a cadre of clinicians and drug treatment advocates impressed with its ability to reverse withdrawal symptoms and craving for alcohol and various drugs of abuse. It has been used outside of the U.S. to treat addiction by American and other clinicians. But its side effects, including hallucinations, which made it popular in the 1960s drug culture, and evidence of toxicity to certain nerve cells in rodent studies have discouraged careful studies of its clinical potential against drug and alcohol addiction. The FDA has not approved use of Ibogaine in the U.S. Scientists at UCSF's Ernest Gallo Clinic and Research Center have now shown definitively in experiments with mice and rats that Ibogaine does reduce alcohol consumption, and they have determined that it does so by increasing the level of a brain protein known as glial cell line-derived neurotrophic factor, or GDNF. In a separate study, they demonstrated that G DNF by itself decreases alcohol consumption. The research is being published in the January 19 issue of The Journal of Neuroscience. "By identifying the brain protein that Ibogaine regulates to reduce alcohol consumption in rats, we have established a link between GDNF and reversal of addiction -- knowledge of a molecular mechanism that should allow development of a new class of drugs to treat addiction without Ibogaine's side effects," said Dorit Ron, PhD, UCSF associate professor of neurology and also principal investigator at the Gallo Center. Ron is co-senior author of the paper with Patricia Janak, PhD, UCSF assistant professor of neurology and also principal investigator at the Gallo Center. In their research, the scientists first carried out classic behavioral studies showing that Ibogaine reduced alcohol consumption. They induced the rats to consume alcohol in daily drinking sessions and then demonstrated that their drinking declined precipitously when they received Ibogaine. The drug was administered either by injection or directly into the same brain region where GDNF levels were shown to increase. The research also showed that Ibogaine was quite effective in preventing relapse, or "falling off the wagon" -- the vulnerability of recovered alcoholics or addicts to return to uncontrolled drinking or drug use when exposed to the drug of abuse months or even years after breaking the habit. In this analysis, the researchers provided alcohol to rats until they had become "experienced" daily drinkers. They then withheld alcohol for two weeks, which normally leads to greatly increased drinking when when alcohol is again available. When they administered Ibogaine, they found that the heightened craving and consumption was significantly reduced. "The discovery that Ibogaine reduced binge drinking after a period of abstinence was an exciting finding for us because this is the type of behavior in alcoholics for which very few effective drugs exist," Janak said. The sc ientists confirmed in a cell model that Ibogaine stimulated GDNF activity. Finally, they showed that a known inhibitor of GDNF blocked Ibogaine's ability to decrease alcohol craving in the rats, suggesting a direct link between Ibogaine's desirable actions and GDNF. "If we can alter the GDNF pathway, we may well have a new treatment against alcohol and drug addiction without the unwanted side effects of Ibogaine," Ron said. Colleagues in the research and coauthors on the paper are postdoctoral fellows Dao-Yao He, PhD, Nancy N.H. McGough, PhHD; Ajay Ravindranathan, PhD; Jerome Jeanblanc, PhD; Marian Logrip, BA, UCSF neurology graduate student; and Khanhky Phamluong, BA, research associate, all at the Gallo Center. The research is supported by funds provided by the State of California through UCSF for medical research on alcohol and substance abuse, and by the Department of Defense.

Source:University of California, San Francisco

Related biology news :

1. Enzyme, lost in most mammals, is shown to protect against UV-induced skin cancer
2. Topical treatment shown to inhibit HIV and herpes simplex virus infection
3. Enzyme shown to help protect genomic stability
4. Novel gene-silencing nanoparticles shown to inhibit Ewings sarcoma
5. New imaging technology shown to detect pancreatic inflammation in type 1 diabetes
6. First direct mechanical communication of mitochondria, cardiomyocyte nucleus shown
7. Ultra low-dose estrogen shown safe for post-menopausal women
8. Vaccine shown effective against chancroid
9. Protein shown to rally biological clock
10. Active ingredient in common Chinese herb shown to reduce hypertension
11. Mouse brain cells rapidly recover after Alzheimers plaques are cleared

Post Your Comments:

(Date:11/9/2015)...  Synaptics Inc. (NASDAQ: SYNA ), the leading ... into the automotive market with a comprehensive and dedicated ... consumer electronics human interface innovation. Synaptics, industry-leading touch controllers, ... automotive industry and will be implemented in numerous locations ... , Japan , and ...
(Date:10/29/2015)... Oct. 29, 2015  The J. Craig Venter Institute ... "DNA Synthesis and Biosecurity: Lessons Learned and Options for ... Health and Human Services guidance for synthetic biology providers ... --> --> Synthetic ... the potential to pose unique biosecurity threats. It now ...
(Date:10/29/2015)... NXTD ) ("NXT-ID" or ... the growing mobile commerce market and creator of ... leading marketplace to discover and buy innovative technology ... on StackSocial for this holiday season.   ... a biometric authentication company focused on the growing ...
Breaking Biology News(10 mins):
(Date:11/26/2015)... MUMBAI , November 26, 2015 ... --> Accutest Research ... accredited Contract Research Organization (CRO), has ... Chase Cancer Center - Temple Health ... ,     (Photo: ) ...
(Date:11/25/2015)... --> ... 2020 report analyzes that automating biobanking workflow will ... long-term samples, minimizing manual errors, improving the workflow ... errors such as mislabeling or inaccurate sample barcoding ... a vital role in blood fractionation, DNA extraction, ...
(Date:11/25/2015)... 25, 2015 2 nouvelles études permettent ... les différences entre les souches bactériennes retrouvées dans la ... des êtres humains . Ces recherches  ouvrent une nouvelle ... prise en charge efficace de l,un des problèmes ... chats .    --> 2 nouvelles études ...
(Date:11/25/2015)... HOLLISTON, Mass. , Nov. 25, 2015 /PRNewswire/ ... ), a biotechnology company developing bioengineered organ implants for ... will present at the LD Micro "Main Event" ... p.m. PT. The presentation will be webcast live and ... will also be available at the conference for one-on-one ...
Breaking Biology Technology: